Functionally, the combination treatment led to a significant increase in IFNγ+CD8+ T cells (Fig. 6K), further supporting the anti-tumor immune reprogramming of the TME of HCC induced by this therapeutic approach. The gene discussed is CD8A; the disease is hepatocellular carcinoma.